Search Results
Your search for ,NOt matches 22378 pages
Showing 5301 - 5350Innovation Can Advance Equitable Cancer Care
The North Star of an organization is its mission statement. At ASCO, no initiative gets the green light unless it can fulfill the Society’s mission. ASCO updated its mission statement in 2020 specifically to reinforce our goal of reducing disparities, changing it to read: “Conquering cancer through ...
An Emergency Room Physician Offers Hands-on Perspective for Treating Patients With Cancer
According to research in the literature, adults with cancer generate high rates of emergency department visits, leading to hospitalization roughly 60% of the time—nearly four times the rate of the general population. Although many of these visits could be prevented, this phenomenon offers numerable ...
Expert Point of View: David Paul Carbone, MD, PhD
“Progress in lung cancer happens by slow steps punctuated by quantum leaps. In the age of perioperative therapies, we are moving one step closer to curing more patients. Surgery is still the intervention most likely to cure patients with earlier-stage disease, but 50% of cases can recur,” said...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy Improves Event-Free Survival Over Chemotherapy Alone in Resectable NSCLC
The combination of neoadjuvant nivolumab plus chemotherapy achieved statistically significant and clinically meaningful improvement in event-free survival vs chemotherapy alone (P = .005) in patients with resectable non–small cell lung cancer (NSCLC, stage IB–IIIA), according to the results of the ...
Long-Term Overall Survival in Unresectable Stage III NSCLC With Consolidation Durvalumab in the PACIFIC Trial: Translation to Real-World Outcomes?
Lung cancer mortality rates have declined by more than 50% in men since 1990 and more than 30% in women since 2002. These declines in mortality are largely due to increases in smoking cessation. However, in recent years, clinical treatment advances, such as targeted therapies and immunotherapy,...
PD-1 Inhibition in First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: More to Come on New Paradigm
Esophageal cancer is associated with significant morbidity and mortality worldwide, with more than 600,000 new cases and 540,000 deaths in 2020. The squamous cell histology comprises nearly 90% of cases globally, despite its steady decline in the United States over the past 40 years. Historically,...
5-Year Survival Outcomes With Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
As reported in the Journal of Clinical Oncology by David R. Spigel, MD, of Sarah Cannon Research Institute/Tennessee Oncology, and colleagues, long-term follow-up of the phase III PACIFIC trial has shown maintained progression-free and overall survival benefits with consolidation durvalumab (a...
Overall Survival Benefit With Nivolumab Plus Chemotherapy or Ipilimumab vs Chemotherapy Alone in Esophageal Squamous Cell Carcinoma
As reported in The New England Journal of Medicine by Yuichiro Doki, MD, of Osaka University Graduate School of Medicine, Japan, and colleagues, the phase III CheckMate 648 trial has shown improved overall survival with nivolumab combined with chemotherapy or ipilimumab vs chemotherapy alone in...
Understanding Oncologists’ Perceptions About Palliative Care and the Barriers Preventing Its Use
Despite studies showing the benefits of early palliative care in improving the quality of life of patients with advanced cancer (including reducing symptoms of depression),1 a recent survey of oncologists found there is broad variation in the appropriate utilization of this care.2 Conducted by...
ASCO Sets Goals to Advance the Clinician-Educator Career Pathway in Oncology
Although most oncology program directors and associate or assistant program directors consider themselves clinician-educators, they receive little to no formal medical education training to nurture trainees into clinician-educator careers and do not have a clinician-educator track for their...
The Impact of War on Patients With Cancer
Just days after Russia invaded Ukraine on February 24, ASCO, together with its partners the American Cancer Society (ACS) and the Sidney Kimmel Cancer Center–Jefferson Health, began assembling resources to establish a network of oncology professionals to help Ukrainian patients with cancer find...
Tackling the Global Burden of Cancer on Adolescents and Young Adults With Cancer
Several recent studies examining the global burden of cancer on adolescents and young adults (AYAs) show the growing magnitude of the disease’s impact on the lives of individuals between the ages of 15 and 39. Although considered a rare occurrence, cancer in this age group has risen by...
Pembrolizumab for MSI-H/dMMR Advanced Endometrial Carcinoma
On March 21, 2022, pembrolizumab was approved for patients with advanced endometrial carcinoma that is microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR), as determined by a U.S. Food and Drug Administration (FDA)-approved test, who have disease progression following prior...
Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
On April 1, 2022, axicabtagene ciloleucel was approved for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.1 It is not indicated for the treatment of patients with primary central nervous system...
UC Davis Launches Center for Advancing Cancer Health Equity
To address cancer health disparities in the region, the University of California (UC) Davis Comprehensive Cancer Center is launching the Center for Advancing Cancer Health Equity, which will conduct community-engaged research and interventions using multilevel approaches. The new center will build...
COVID-19 Restrictions Linked to Delayed Breast Cancer Care at Safety-Net Hospital
Millions of elective surgeries and medical procedures were canceled or postponed by the COVID-19 pandemic. Now, research shows that COVID-19 restrictions were also associated with significant delays in breast cancer care.1 Findings of a cohort study, which compared breast cancer care before and...
How St. Jude and the WHO Are Sparking an International Movement to Increase Treatment Access for Children With Cancer
The toll of cancer on children, especially those living in low-resource countries, is staggering. Each year, an estimated 400,000 children and adolescents worldwide develop cancer,1 and despite improved survival rates, the global 5-year net childhood cancer survival rate is only 37.4%,2 making...
Surgical Approach and Overall Survival in Younger Women With Breast Cancer
More extensive surgery does not improve survival over less aggressive surgery in younger women with breast cancer, according to data presented at the 2022 American Society of Breast Surgeons Annual Meeting.1 The results of a retrospective study of nearly 600 patients showed that treatment with...
Expert Point of View: Edward B. Garon, MD
Invited discussant of the NeoCOAST trial, Edward B. Garon, MD, Professor of Medicine and Director of the Thoracic Oncology Program at David Geffen School of Medicine at the University of California Los Angeles, praised the study: “NeoCOAST is an impressive study that showed numerical benefit when...
An Early Love of Science Led to a Career in Breast Cancer Research for Sara M. Tolaney, MD, MPH
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Sara M. Tolaney, MD, MPH, a faculty member of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she is Chief of the Breast Cancer Program. Her current research focuses on the development of novel ...
Combination Therapy of Olaparib, Cyclophosphamide, and Metformin Under Study in Advanced Endometrial Cancer
A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and metformin demonstrated activity in elderly, heavily pretreated patients with recurrent, advanced endometrial...
Radiation Segmentectomy for Very Early– and Early-Stage Hepatocellular Carcinoma
Radiation segmentectomy may be an effective treatment for very early– to early-stage hepatocellular carcinoma (HCC) that cannot be treated surgically or thermally. The findings from a multidisciplinary study by researchers at the Icahn School of Medicine at Mount Sinai were published by Kim et al...
Study Finds Screen-Detected Colorectal Cancers May Have More Favorable Stage Distribution Than Colorectal Cancers Detected Otherwise
In a population-based study conducted in nine European countries for which data on mode of detection were available (Belgium, Denmark, England, France, Italy, Ireland, the Netherlands, Slovenia, and Spain), the proportion of colorectal cancer cases detected by screening varied widely between...
Gabapentin May Be an Effective Alternative to Opioids for Patients With Head and Neck Cancer Receiving Radiation
Patients with head and neck cancer undergoing radiation therapy may be less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, findings from a team of radiation oncologists showed. Their report, published by Ma et al in JAMA ...
Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma
Invited study discussant of the use of ipilimumab plus nivolumab in resistant melanoma, at the AACR Annual Meeting 2022, Mario Sznol, MD, of Yale University Cancer Center, indicated that the substantial increase in progression-free survival at 6 months was not maintained. “The durable...
Approaches to Potentiate Immune Response in Patients Who Do Not Respond to Anti–PD-1 Therapy for Melanoma
A sizable proportion of patients with advanced melanoma will experience disease progression on anti–PD-1 therapy, and the optimal treatment of such patients represents an unmet need. Two studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 explored separate...
Tazemetostat for Patients With Relapsed or Refractory BAP1-Inactivated Malignant Pleural Mesothelioma
In a phase II study reported in The Lancet Oncology, Zauderer et al found that the EZH2 inhibitor tazemetostat was active in patients with relapsed or refractory BRCA-associated protein 1 (BAP1)-inactivated malignant pleural mesothelioma. As noted by the investigators, high expression of EZH2 has...
Adverse Events Seen With Abiraterone or Enzalutamide Among Patients With Advanced Prostate Cancer
Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients who were receiving hormone therapy alone, according to findings...
Report Examines Imaging Approach With Potential to Detect Lung Cancer at the Cellular Level
Researchers have found a way to identify lung cancer at the cellular level in real time during a biopsy, which may enable detection of the disease earlier and with more confidence. The findings, published by Kennedy et al in Nature Communications, demonstrated that an imaging agent detected via...
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
On May 20, the U.S. Food and Drug Administration approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). AZA-JMML-001 Efficacy was evaluated in AZA-JMML-001 (ClinicalTrials.gov identifier NCT02447666), an international, multicenter,...
Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical Trials
Two oncologists who are now heads of oncology development for pharmaceutical companies discussed the future of cancer drugs at the Community Oncology Alliance’s 2022 Community Oncology Conference. They were Johanna Bendell, MD, Global Head of Oncology, Pharma Research, and Early Development at...
Surgery Preference and Surgery Received in Women With DCIS
In an ancillary study of the ECOG-ACRIN Cancer Research Group E4112 study reported in JAMA Network Open, Fazeli et al found that patient preference of type of surgery and type of surgery received for ductal carcinoma in situ (DCIS) were influenced by preoperative magnetic resonance imaging (MRI)...
NCCN Clinical Practice Guidelines in Oncology: 2022 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...
Study Points to Expanded Genomic Testing to Benefit Children and Young Adults With Cancer
New findings from researchers at Memorial Sloan Kettering Cancer Center published by Shukla et al in Nature Communications reported the results of using a comprehensive sequencing approach on 114 pediatric, adolescent, and young adult patients with solid tumors. The researchers found that their...
Medicaid Expansion Is Associated With Increased Survival in Newly Diagnosed Patients With Cancer
A large study led by researchers at the American Cancer Society showed that Medicaid expansion under the Affordable Care Act (ACA) was associated with an increase in 2-year overall survival rates among patients newly diagnosed with cancer, especially among non-Hispanic Black people and people...
Using a Transcriptomic Profile to Identify Plasma Cell Leukemia–Like Disease in Patients With Newly Diagnosed Multiple Myeloma
In a study reported in the Journal of Clinical Oncology, Bruinink et al constructed a transcriptomic classifier for primary plasma cell leukemia (PCL) that identified high-risk PCL-like disease in patients with newly diagnosed multiple myeloma. As stated by the investigators, “Primary PCL is an...
The Future of Community Oncology Practice
Although community oncology practice may have been changing before the COVID-19 pandemic, it amplified industry trends. At the 2022 Community Oncology Alliance’s Community Oncology Conference, a panel of experts discussed issues related to the future of community cancer care, including...
Study Investigates Possible Link Between Risk of Breast Cancer in Males and Male Infertility
The risk of invasive breast cancer in men may be associated with self-reported infertility, according to a study published by Swerdlow et al in the journal Breast Cancer Research. The authors interviewed 1,998 males in England and Wales diagnosed with breast cancer, with 112 (5.6%) also...
Guideline-Concordant Treatment of Women With Nonmetastatic Breast Cancer in Sub-Saharan Africa
As reported in The Lancet Oncology by Foerster et al, the African Breast Cancer–Disparities in Outcomes prospective cohort study has shown that a high proportion of women with newly diagnosed nonmetastatic breast cancer in sub-Saharan Africa did not initiate, did not fully complete, or abandoned...
CoVac-1 Vaccination Studied for Prevention of Severe COVID-19 in Immune-Deficient Patients With Cancer
CoVac-1, a multipeptide COVID-19 vaccine candidate, elicited immunogenicity in patients with cancer and disease-related or treatment-related immunoglobulin deficiency in a phase I/II trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 These patients are...
Colonoscopy After Positive FIT Test May Reduce Risk of Death From Colorectal Cancer
Recent research underlines the importance of following up with a colonoscopy exam after a positive result on an at-home stool test to screen for colorectal cancer. The test, known as the fecal immunochemical test (FIT), checks for traces of blood in patient-collected stool samples, which can be an...
Report Finds Uptake of Erdafitinib for Urothelial Cancer May Be Limited, Despite Positive Real-World Survival Data
The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a report published as a research letter by Nimgaonkar et al in JAMA Oncology. Researchers analyzed a large, nationwide database of cancer...
Addition of ADT and Pelvic Lymph Node Radiotherapy to Salvage Prostate Bed Radiotherapy After Prostatectomy
In a phase III trial (NRG Oncology/RTOG 0534 SPPORT) reported in The Lancet, Alan Pollack, MD, PhD, and colleagues found that both the addition of short-term androgen-deprivation therapy (ADT) and the addition of ADT and pelvic lymph node radiotherapy (PLNRT) to salvage prostate bed radiotherapy...
Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors
The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...
Delays in Surgery for Advanced Esophageal Cancer Result in Significantly Worse Survival
Delays in surgery for esophageal cancer did not appear to have much impact on patients’ relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an...
Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma
A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...
AYA Leukemia Survivors Have Higher Mortality Rates Than the General Population
Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...
Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer
The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...
3 vs 6 Months of Adjuvant Oxaliplatin- and Fluoropyrimidine-Based Therapy for Stage III Colon Cancer: Final Analysis
As reported in the Journal of Clinical Oncology by Yoshino et al, the final analysis of survival and safety of the Japanese phase III ACHIEVE trial (part of the IDEA Collaboration) has shown no difference in disease-free or overall survival with 3 vs 6 months of adjuvant mFOLFOX6 (fluorouracil,...
Sentinel Node May Not Be Informative in Making Treatment Decisions for Some Breast Cancer Subsets
In women aged 70 and older with hormone receptor–positive, HER2-negative, low-risk breast cancers, sentinel lymph node biopsy may not be a reliable indicator of the need for adjuvant chemotherapy, researchers reported at the 2022 American Society of Breast Surgeons Annual Meeting.1 “We found that...
